Selected article for: "clinical study and viral infection"
Author: Chee, Jeremy; Loh, Woei Shyang; Liu, Zheng; Mullol, Joaquim; Wang, De Yun
Title: Clinical-Pathological Correlation of the Pathophysiology and Mechanism of Action of COVID-19 — a Primer for Clinicians
  • Cord-id: 6njfoa22
  • Document date: 2021_7_14
    • ID: 6njfoa22
    Snippet: PURPOSE OF REVIEW: Increasing knowledge of the pathogenesis of the SARS-CoV-2 infection and the complex interaction between host and viral factors have allowed clinicians to stratify the severity of COVID-19 infection. Epidemiological data has also helped to model viral carriage and infectivity. This review presents a comprehensive summary of the pathophysiology of COVID-19, the mechanisms of action of the SARS-CoV-2 virus, and the correlation with the clinical and biochemical characteristics of
    Document: PURPOSE OF REVIEW: Increasing knowledge of the pathogenesis of the SARS-CoV-2 infection and the complex interaction between host and viral factors have allowed clinicians to stratify the severity of COVID-19 infection. Epidemiological data has also helped to model viral carriage and infectivity. This review presents a comprehensive summary of the pathophysiology of COVID-19, the mechanisms of action of the SARS-CoV-2 virus, and the correlation with the clinical and biochemical characteristics of the disease. RECENT FINDINGS: ACE2 and TMPRSS2 receptors have emerged as a key player in the mechanism of infection of SARS-CoV-2. Their distribution throughout the body has been shown to impact the organ-specific manifestations of COVID-19. The immune-evasive and subsequently immunoregulative properties of SARS-CoV-2 are also shown to be implicated in disease proliferation and progression. SUMMARY: Information gleaned from the virological properties of SARS-CoV-2 is consistent with and reflects the clinical behavior of the COVID-19 infection. Further study of specific clinical phenotypes and severity classes of COVID-19 may assist in the development of targeted therapeutics to halt progression of disease from mild to moderate-severe. As the understanding of the pathophysiology and mechanism of action of SARS-CoV-2 continues to grow, it is our hope that better and more effective treatment options continue to emerge.

    Search related documents:
    Co phrase search for related documents
    • accumulation vascular permeability and acute respiratory syndrome: 1, 2
    • active replication and acute ards respiratory distress syndrome: 1, 2
    • active replication and acute phase: 1
    • active replication and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active replication and acute sars cov respiratory syndrome virus: 1, 2
    • active replication and liver disease: 1
    • active replication and liver kidney: 1
    • active replication and local infection: 1
    • acute ards respiratory distress syndrome and additional factor: 1, 2
    • acute ards respiratory distress syndrome and adjunctive treatment: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and admission sofa score: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute ards respiratory distress syndrome and liver kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute phase and adjunctive treatment: 1, 2
    • acute phase and admission time: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and liver disease: 1, 2, 3, 4, 5, 6
    • acute phase and liver kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute phase and local infection: 1, 2, 3, 4, 5, 6, 7, 8